Together with the cohorts described above, this project uses the infrastructure of the DPUK PET-MR Imaging network (UCL, Imperial, Cambridge, Manchester, Newcastle and Edinburgh). The study team use a new compound for PET imaging in Alzheimer’s disease - the imaging agent PI-2620 - that is in development by Life Molecular Imaging.
Tau-PET imaging
Researchers will carry out additional PET scanning of 100 people who have already had PET scans as part of their involvement in two existing health study cohorts – EPAD and PREVENT. The extra information they collect on the 'tau' protein, when combined with existing data from these participants, will create a very rich dataset for modelling the early stages of Alzheimer's disease and subsequent dementia.
©
Malhotra